Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
10 2022
Historique:
received: 18 06 2022
revised: 30 07 2022
accepted: 07 08 2022
pubmed: 16 8 2022
medline: 5 10 2022
entrez: 15 8 2022
Statut: ppublish

Résumé

Interval debulking surgery is recommended after 3-4 cycles (standard IDS) of neoadjuvant chemotherapy (NACT) for epithelial ovarian cancer (EOC) not able to received upfront complete debulking surgery. However, real world practices frequently report performing IDS after ≥5 NAC cycles (delayed IDS). The aim of this work was to evaluate the impact on survival of the number of NACT cycles before IDS. We identified from a French national database, women with newly diagnosed EOC who underwent IDS from January 2011 to December 2016. Progression free survival (PFS) and overall survival (OS) were compared using Cox model with adjustments for confounding factors provided by two propensity score methods: inverse probability of treatment weighting (IPTW) and matched-pair analysis. 928 patients treated by IDS for which our propensity score could be applied were identified. After a median follow-up of 49.0 months (95% CI [46.0;52.9]); from the IPTW analysis, median PFS was 17.6 months and 11.5 months (HR = 1.42; CI 95% [1.22-1.67]; p < 0.0001); median OS was 51.2 months and 44.3 months (HR = 1.29; CI 95% [1.06-1.56]; p = 0.0095) for the standard and delayed IDS groups. From the matched-pair analysis (comparing 352 patients for each group), standard IDS was associated with better PFS (HR = 0,77; CI 95% [0.65-0.90]; p = 0.018) but not significantly associated with better OS (HR = 0,84; CI 95% [0.68-1,03]; p = 0.0947). Carrying IDS after ≥5 NACT cycles seems to have a negative effect on patients survival. The goal of IDS surgery is complete resection and should not be performed after >3-4 NACT cycles.

Identifiants

pubmed: 35970603
pii: S0090-8258(22)00543-1
doi: 10.1016/j.ygyno.2022.08.005
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11-21

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest All the authors declare that they have no conflicts of interest to disclose related to this work.

Auteurs

Quentin Dominique Thomas (QD)

Departement of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France. Electronic address: quentin.thomas@icm.unicancer.fr.

Amal Boussere (A)

Department of Biometry, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.

Jean-Marc Classe (JM)

Department of Surgical Oncology, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint Herblain, France.

Christophe Pomel (C)

Department of Surgical Oncology, Centre de Lutte Contre le Cancer Jean Perrin, Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, UMR INSERM-UCA, Clermont-Ferrand, France.

Hélène Costaz (H)

Department of Surgical Oncology, Centre Georges-François Leclerc, Dijon, France.

Manuel Rodrigues (M)

Department of Medical Oncology, Institut Curie, Paris, France.

Isabelle Ray-Coquard (I)

Department of Medical Oncology, Centre Léon Bérard, Lyon, France.

Laurence Gladieff (L)

Department of Medical Oncology, Institut Claudius Régaud IUCT-O, Toulouse, France.

Roman Rouzier (R)

Department of Surgical Oncology, Centre François Baclesse, Caen, France.

Thibault De La Motte Rouge (TM)

Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.

Sébastien Gouy (S)

Department of Surgery, Gustave Roussy, Villejuif, France.

Emmanuel Barranger (E)

Departement of Surgery, Centre Antoine Lacassagne, Nice, France.

Renaud Sabatier (R)

Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.

Anne Floquet (A)

Department of Medical Oncology, Institut Bergonié, Bordeaux, France.

Frédéric Marchal (F)

Departement of Surgery, Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France.

Cécile Guillemet (C)

Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.

Valentine Polivka (V)

Department of Biometry, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.

Anne-Laure Martin (AL)

Health Data and Partnership Department, Unicancer, Paris, France.

Pierre-Emmanuel Colombo (PE)

Departement of Surgery, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.

Frédéric Fiteni (F)

Departement of Medical Oncology, University Hospital of Nîmes, University of Montpellier, UMR UA11 INSERM, IDESP Institut Desbrest d'Epidémiologie et de Santé Publique, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH